CD8A and cancer: Among CT antigens, NY-ESO-1, a SEREX-defined CT antigen, was shown to induce a frequent antibody response in cancer patients[23,24], and strong CD4 and CD8 T-cell responses against NY-ESO-1 were also elicited[25,26].